We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 225% above its sector, the market expects faster growth.
Chongqing Pharscin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the research, development, manufacturing, and distribution of medicines. Its product portfolio encompasses a broad spectrum of pharmaceutical formulations, such as tablets, powders, granules, hard and soft capsules, alongside various injectables including powder, freeze-dried powder, and small volume injections. The company also specializes in active pharmaceutical ingredient (API) synthesis. This diverse range of products targets critical therapeutic areas, including the central nervous system (CNS), digestive health, otolaryngology, oncology, as well as cardiovascular and cerebrovascular conditions. Established in 1996, the company maintains its headquarters in Chongqing, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 002907.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
